Title - drug development support for the cancer therapy evaluation program (ctep)

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201500006C
Awardee
Awarding agency
Obligated
$48,485,098

Award facts

Opportunity
Contract value 88% obligated
  • $48,485,098.18 Current, with exercised options
  • $55,311,391.18 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Westlake, MD 20817, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00027 -$467,742
Funding Only Action P00026 -$309,015
Funding Only Action P00025 -$234,350
Other Administrative Action P00024 $0
Other Administrative Action P00023 · Drug development support for the cancer therapy evaluation program (ctep) -$335,666
Other Administrative Action P00022 · IPP and drug development support for the cancer therapy evaluation program (ctep) $0
Other Administrative Action P00021 $0
Exercise an Option P00020 $7,562,000
Change Order P00019 $0
Other Administrative Action P00018 -$71,845
Funding Only Action P00017 · Drug development support for the cancer therapy evaluation program (ctep) $8,086,500
Change Order P00016 $0
Exercise an Option P00015 $7,540,896
Vendor DUNS or Name Change - Non-Novation P00014 $0
Funding Only Action P00013 $250,742
Other Administrative Action P00012 $0
Exercise an Option 11 $7,755,937
Other Administrative Action 10 $0
Change Order 9 $6,309,387
Other Administrative Action 8 $0
Exercise an Option 7 $1,000,000
Other Administrative Action 6 $0
Funding Only Action 5 $336,251
Exercise an Option 4 $5,503,604
Funding Only Action 3 $175,000
Other Administrative Action 2 $0
Other Administrative Action 1 · Other function - drug development support for the cancer therapy evaluation program (ctep) $0
Original award $5,383,400
Show all 28

About this award

Written by GovTribe AI ·

The National Cancer Institute (NCI) awarded a $55,311,391.18 cost-plus-fixed-fee contract to Technical Resources International, Inc. (TRI) for Drug Development Support for the Cancer Therapy Evaluation Program (CTEP). The contract, which runs through September 30, 2022, provides comprehensive clinical research support services to NCI, including clinical trials execution, regulatory support, research operations, and specialized scientific services. TRI, a minority-owned, woman-owned, and Hispanic American-owned small business, has extensive experience supporting biomedical research initiatives for various federal health agencies. The contract is not set aside. TRI holds several significant Indefinite Delivery Vehicles (IDVs) with NCI, the National Institute of Allergy and Infectious Diseases (NIAID), and the Office of the Assistant Secretary for Preparedness and Response (ASPR), which enable rapid procurement of its services across federal health agencies for critical research initiatives in areas such as HIV, cancer, and emerging infectious diseases.

Quick answers

Who was awarded contract HHSN261201500006C?

HHSN261201500006C was awarded to Technical Resources International, Inc. by National Cancer Institute (National Institutes of Health) on July 1, 2015.

How much is contract HHSN261201500006C worth?

The government has obligated $48,485,098 on HHSN261201500006C. Its potential value, with all options, is $55,311,391.

Was contract HHSN261201500006C competed?

The extent of competition for HHSN261201500006C was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login